
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 18 March 2024
Sec. Molecular and Cellular Oncology
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1395244
This article is a correction to:
miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer
A corrigendum on
miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer
by Choi S, Lee S, Han Y-H, Choi J, Kim I, Lee J and An H-J (2022) Front. Oncol. 12:945057. doi: 10.3389/fonc.2022.945057
In the published article, there was a mistake in Figure 4 as published. The image of LNCap co-transfected with empty vector and control miRNA in Panel C was mistakenly mixed up with the image of the LNCap co-transfected with GABBR2 vector and miR-31-3p in Panel D. The corrected Figure 4 appears below.
Figure 4 miR-31-3p-induced tumor suppressive functions are associated with downregulation of GABBR2. (A) Restoration of GABBR2, p-ERK and p-JNK protein levels after ectopic expression of Myc-DDK-tagged-GABBR2. DU145, PC-3 and LNCap cells were transfected with a mixture of miR-31-3p (20 nM) and GABBR2 expression vector (4 μg). An unpaired two-tailed Student’s t-test was used to calculate P values. Error bars represent mean ± SEM. *P value < 0.05, **P value < 0.01 and ***P value < 0.001 vs. Cont (n = 3). (B) Ectopic expression of GABBR2 suppresses miR-31-3p-induced apoptosis of DU145, PC-3, and LNCap cells. An unpaired two-tailed Student’s t-test was used to calculate P values. Error bars represent mean ± SEM. ***P value < 0.001 vs. Cont (n = 3). (C, D) Ectopic expression of GABBR2 restores miR-31-3p-mediated inhibition of PC cell migration and invasion. An unpaired two-tailed Student’s t-test was used to calculate P values. Error bars represent mean ± SEM. *P value < 0.05, **P value < 0.01 and ***P value < 0.001 vs. Cont (n = 3).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: miR-31-3p, GABBR2, prostate cancer, miRNA, tumor suppressor gene
Citation: Choi S, Lee S, Han Y-H, Choi J, Kim I, Lee J and An H-J (2024) Corrigendum: miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer. Front. Oncol. 14:1395244. doi: 10.3389/fonc.2024.1395244
Received: 03 March 2024; Accepted: 05 March 2024;
Published: 18 March 2024.
Edited and Reviewed by:
Kirill Afonin, University of North Carolina at Charlotte, United StatesCopyright © 2024 Choi, Lee, Han, Choi, Kim, Lee and An. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hyun-Ju An, eWtzNDg2YWhqQG5hdmVyLmNvbQ==
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.